AstraZeneca to end distribution of rare blood cancer med Lumoxiti in August
Christopher Furlong         

AstraZeneca (NASDAQ:AZN) will discontinue supplying Lumoxiti (moxetumomab pasudotox), approved for hairy cell leukemia, in the US in August.
The drug was approved in September 2018.
The treatment's removal is not due to safety or efficacy issues, according to the company. Rather, AstraZeneca (AZN) said that it is due to low uptake and availability of other treatments, a Dear Healthcare Provider Letter states.
AstraZeneca is also ending a post-marketing study of the treatment.

The company added that using Roche's (OTCQX:RHHBY) Zelboraf (vemurafenib) in combination with Rituxan (rituximab) is a preferred option in lieu of Lumoxiti.